What do systematic reviews say?

Summary of findings: Inhaled antibiotics vs IV antibiotics

• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 59 participants
  Very low

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

• Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 82 participants
  Moderate

Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 259 participants
  Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs nebuliser

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: oral β‐carotene vs placebo

The review found no eligible studies for this question.

• Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral azithromycin vs placebo

• Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 796 participants
  Moderate

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Inhaled antibiotics plus IV antibiotics vs IV antibiotics

• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Low

Summary of findings: inhaled antioxidants vs placebo

The review found no eligible studies for this question.

• Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulised azithromycin vs azithromycin

The review found no eligible studies for this question.

• Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: oral antioxidants (NAC/GSH) vs placebo

The review found no eligible studies for this question.

• Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: oral antioxidant combination vs control

The review found no eligible studies for this question.

• Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found